Atacand (candesartan) Real Life Study - Real Life

Study identifier:NIS-CSE-ATA-2008/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A REtrospective study on the effects of cAndesartan vs. Losartan on blood pressure, health care consumption and cardiovascuLar events In a "real-liFe" GP sEtting in Sweden

Medical condition

hypertension

Phase

Healthy volunteers

Study drug

Candesartan Cilexetil, Losartan

Sex

All

Actual Enrollment

14000

Study type

Observational

Age

17 Years +

Date

Study Start Date: 01 Mar 2008

Primary Completion Date: 01 Feb 2009

Study Completion Date: 01 Feb 2009

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Uppsala, Sweden

Arms	Assigned Interventions
1 Candesartan	Drug: Candesartan Cilexetil oral once daily dose Other Name: ATACAND
2 Losartan	Drug: Losartan once daily oral dose Other Name: COZAAR

"There is no result for the study"

Documents available

CSR-NIS-CSE-ATA-2008-1.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Norway Study Information

+ 47 21 00 64 00

paal.hasvold@astrazeneca.com

Contact Backup

Statisticon AB - Marianne Mæhle-Schmidt

+ 46 18 182230

marianne.maehle-schmidt@statisticon.se

Investigators

Principal Investigator

Jan Stålhammar

Eriksbergs vårdcentral